Want to see NXTC full AI Analyst Report?
NXTC Stock Chart & Stats
$5.83
$0.70(16.51%)
At close: 4:00 PM EDT
$5.83
$0.70(16.51%)
Day’s Range― - ―
52-Week Range$1.55 - $15.74
Previous CloseN/A
Volume127.65K
Average Volume (3M)298.06K
Market Cap
$35.79M
Enterprise Value-$7.31
Total Cash (Recent Filing)$20.09M
Total Debt (Recent Filing)$4.29M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Oct 29, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.58
Shares Outstanding4,577,359
10 Day Avg. Volume101,015
30 Day Avg. Volume298,056
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.50Price Target Upside200.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-6.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageRelatively modest leverage limits fixed financial obligations compared with highly indebted peers and provides some balance-sheet flexibility. This can help preserve strategic options while the company develops its pipeline, although the benefit is tempered by ongoing losses and shrinking equity.
Merger Funding And Pipeline ExpansionThe transaction would provide substantial capital and add Avere’s oral IL-23 program, extending development toward multiple clinical milestones in psoriasis and ulcerative colitis. That funding and broader pipeline could improve operating durability if clinical execution succeeds.
Operating-cost ReductionExiting the Beltsville facility removes future rent commitments and consolidates the company’s physical footprint. Lower recurring infrastructure costs can extend available capital and support a more disciplined operating model during the company’s strategic transition.
Bears Say
No Commercial RevenueThe absence of operating revenue means NextCure has not established a commercial product base to fund research and development. Continued dependence on clinical progress and external capital leaves earnings power unproven and makes durable profitability difficult to assess.
Persistent Cash Burn And Equity ErosionSustained cash consumption indicates the business is not self-funding, while the sharply reduced equity cushion shows that shareholder capital has been materially consumed. Unless operations or financing change the trajectory, future development remains dependent on additional capital.
Major Ownership ResetThe merger substantially changes the economic ownership and strategic identity of the company, leaving legacy NextCure investors with only a small stake and contingent rights. The associated workforce reduction also signals a major retreat from the existing oncology operating structure.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $1.55 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $35.79M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Oct 29, 2026 which is in 50 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Aug 06, 2026. The company reported -$2.8 earnings per share for the quarter, missing the consensus estimate of -$1.95 by -$0.85.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -0.9.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 4,577,359 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$2.8 in its last earnings report, missing expectations of -$1.95. Following the earnings report the stock price went up 4.472%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NextCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (200.17% Upside)
$17.50 (200.17% Upside)
Blogger Sentiment
Bullish
NXTC Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 27.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
58.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-52.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
NXTC Stock 12 Month Forecast
Average Price Target
$17.50
▲(200.17% Upside)
Technical Analysis
GT Biopharma
―
Marker Therapeutics
―
Celularity
―
Werewolf Therapeutics
―
Senti Biosciences
―
Ownership Overview
22.53% Insiders
7.86% Mutual Funds
22.80% Other Institutional Investors
43.17% Public Companies and
Individual Investors